Modeling the bacterial dynamics in the gut microbiota following an antibiotic-induced perturbation.


Journal

CPT: pharmacometrics & systems pharmacology
ISSN: 2163-8306
Titre abrégé: CPT Pharmacometrics Syst Pharmacol
Pays: United States
ID NLM: 101580011

Informations de publication

Date de publication:
07 2022
Historique:
revised: 23 03 2022
received: 18 01 2022
accepted: 19 04 2022
pubmed: 19 5 2022
medline: 20 7 2022
entrez: 18 5 2022
Statut: ppublish

Résumé

Recent studies have highlighted the importance of ecological interactions in dysbiosis of gut microbiota, but few focused on their role in antibiotic-induced perturbations. We used the data from the CEREMI trial in which 22 healthy volunteers received a 3-day course of ceftriaxone or cefotaxime antibiotics. Fecal samples were analyzed by 16S rRNA gene profiling, and the total bacterial counts were determined in each sample by flux cytometry. As the gut exposure to antibiotics could not be experimentally measured despite a marked impact on the gut microbiota, it was reconstructed using the counts of susceptible Escherichia coli. The dynamics of absolute counts of bacterial families were analyzed using a generalized Lotka-Volterra equations and nonlinear mixed effect modeling. Bacterial interactions were studied using a stepwise approach. Two negative and three positive interactions were identified. Introducing bacterial interactions in the modeling approach better fitted the data, and provided different estimates of antibiotic effects on each bacterial family than a simple model without interaction. The time to return to 95% of the baseline counts was significantly longer in ceftriaxone-treated individuals than in cefotaxime-treated subjects for two bacterial families: Akkermansiaceae (median [range]: 11.3 days [0; 180.0] vs. 4.2 days [0; 25.6], p = 0.027) and Tannerellaceae (13.7 days [6.1; 180.0] vs. 6.2 days [5.4; 17.3], p = 0.003). Taking bacterial interaction as well as individual antibiotic exposure profile into account improves the analysis of antibiotic-induced dysbiosis.

Identifiants

pubmed: 35583200
doi: 10.1002/psp4.12806
pmc: PMC9286716
doi:

Substances chimiques

Anti-Bacterial Agents 0
RNA, Ribosomal, 16S 0
Ceftriaxone 75J73V1629
Cefotaxime N2GI8B1GK7

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

906-918

Informations de copyright

© 2022 The Authors. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.

Références

Nat Microbiol. 2018 Nov;3(11):1255-1265
pubmed: 30349083
PLoS One. 2013 Nov 25;8(11):e80201
pubmed: 24282523
PLoS One. 2010 Mar 24;5(3):e9836
pubmed: 20352091
Drugs. 1988;35 Suppl 2:6-11
pubmed: 3396490
PLoS Comput Biol. 2013;9(12):e1003388
pubmed: 24348232
Front Psychiatry. 2019 Jul 17;10:473
pubmed: 31404299
Clin Pharmacol Ther. 2021 Apr;109(4):1045-1054
pubmed: 32617960
PeerJ. 2016 Oct 18;4:e2584
pubmed: 27781170
Microb Pathog. 2017 May;106:171-181
pubmed: 26875998
J Infect Dis. 2009 Aug 1;200(3):390-8
pubmed: 19563257
Antimicrob Agents Chemother. 2018 Sep 24;62(10):
pubmed: 30061286
Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):439-44
pubmed: 24367073
Nucleic Acids Res. 2013 Jan 7;41(1):e1
pubmed: 22933715
CPT Pharmacometrics Syst Pharmacol. 2022 Jul;11(7):906-918
pubmed: 35583200
Nat Rev Microbiol. 2012 Jul 16;10(8):538-50
pubmed: 22796884
Trends Mol Med. 2016 Jun;22(6):458-478
pubmed: 27178527
Science. 2015 Nov 6;350(6261):663-6
pubmed: 26542567
J Antimicrob Chemother. 1980 Sep;6 Suppl A:103-11
pubmed: 6252138
Am J Med. 1984 Oct 19;77(4C):112-6
pubmed: 6093511
Appl Environ Microbiol. 2009 Dec;75(23):7537-41
pubmed: 19801464
Acta Endocrinol (Buchar). 2016 Apr-Jun;12(2):206-214
pubmed: 31149088
ISME J. 2019 Jul;13(7):1845-1856
pubmed: 30877283
Microorganisms. 2016 Jun 15;4(2):
pubmed: 27681914
Science. 2005 Mar 25;307(5717):1915-20
pubmed: 15790844
Antimicrob Agents Chemother. 2019 Sep 23;63(10):
pubmed: 31307985
Drugs. 1988;35 Suppl 2:163-8
pubmed: 3135167
Front Psychiatry. 2019 Feb 11;10:34
pubmed: 30804820
Antimicrob Agents Chemother. 2019 May 24;63(6):
pubmed: 30936104
PLoS Comput Biol. 2018 Feb 16;14(2):e1006001
pubmed: 29451873
Front Microbiol. 2016 Jan 12;6:1543
pubmed: 26793178
Nature. 2017 Nov 23;551(7681):507-511
pubmed: 29143816
Science. 2018 Jan 5;359(6371):91-97
pubmed: 29097494
Cell. 2014 Jul 17;158(2):250-262
pubmed: 25036628
Sci Rep. 2016 Jun 22;6:28426
pubmed: 27329053

Auteurs

Jinju Guk (J)

Université de Paris, IAME, INSERM, Paris, France.

Antoine Bridier-Nahmias (A)

Université de Paris, IAME, INSERM, Paris, France.

Mélanie Magnan (M)

Université de Paris, IAME, INSERM, Paris, France.

Nathalie Grall (N)

Université de Paris, IAME, INSERM, Paris, France.
AP-HP, Hôpital Bichat, Laboratoire de Bactériologie, Paris, France.

Xavier Duval (X)

Université de Paris, IAME, INSERM, Paris, France.
AP-HP, Hôpital Bichat, Centre d'Investigation Clinique, Inserm CIC 1425, Paris, France.

Olivier Clermont (O)

Université de Paris, IAME, INSERM, Paris, France.

Etienne Ruppé (E)

Université de Paris, IAME, INSERM, Paris, France.
AP-HP, Hôpital Bichat, Laboratoire de Bactériologie, Paris, France.

Camille d'Humières (C)

Université de Paris, IAME, INSERM, Paris, France.
AP-HP, Hôpital Bichat, Laboratoire de Bactériologie, Paris, France.

Olivier Tenaillon (O)

Université de Paris, IAME, INSERM, Paris, France.

Erick Denamur (E)

Université de Paris, IAME, INSERM, Paris, France.
AP-HP, Hôpital Bichat, Laboratoire de Génétique Moléculaire, Paris, France.

France Mentré (F)

Université de Paris, IAME, INSERM, Paris, France.
Département d'Épidémiologie, AP-HP, Hôpital Bichat, Biostatistique et Recherche Clinique, Paris, France.

Jérémie Guedj (J)

Université de Paris, IAME, INSERM, Paris, France.

Charles Burdet (C)

Université de Paris, IAME, INSERM, Paris, France.
Département d'Épidémiologie, AP-HP, Hôpital Bichat, Biostatistique et Recherche Clinique, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH